GATA28 Antibody

GATA Transcription Factor Antibodies

GATA antibodies target members of the GATA-binding protein family, which regulate gene expression in hematopoietic and immune cells. Key subtypes include:

GATA3 Antibodies

• Function: Critical for T-cell development and Th2 differentiation. Binds enhancers of T-cell receptor genes (α, β, γ, δ) .

• Commercial Availability:

  Product	Clone ID	Applications (Validated)	Species Reactivity
  MA1-028 (Thermo)	1A12-1D9	WB, IP, IHC, IF	Human
  ab282110 (Abcam)	L50-823	WB, IF, IHC-Paraffin	Human

• Western Blot Data: Detects ~50 kDa protein in SH-SY5Y and MCF7 cells, with variable cross-reactivity at 37 kDa .

GATA2 Antibodies

• Function: Regulates hematopoiesis and endothelial cell differentiation .

• Commercial Availability:

  Product	Clone ID	Applications (Validated)	Species Reactivity
  NBP1-82581	Polyclonal	WB, IHC, ICC/IF	Human, Mouse
  MAB2046 (R&D)	527530	WB, ELISA	Human, Mouse

• Western Blot Data: Detects ~51–58 kDa bands in KG-1 and SH-SY5Y cells .

CD28 Superagonist Antibodies

CD28 antibodies targeting the T-cell co-stimulatory receptor have been studied for immunotherapy, with notable examples:

TGN1412

• Mechanism: Superagonistic antibody inducing cytokine storm via sustained Ca++ signaling and NF-κB activation .

• Key Findings:

  • Cytokine Release: Rapid production of IFN-γ, TNF-α, and IL-2 in human CD4+ T cells .

  • Species Specificity: Fails to activate cynomolgus monkey T cells due to CD28 downregulation in CD4+ EM cells .

ANC28.1

• Comparison to TGN1412:

  Parameter	ANC28.1	TGN1412
  IFN-γ Production	Higher	Lower
  IL-10 Induction	Moderate	Strong
  Preclinical Safety	Not tested in humans	Caused CRS in Phase I trial

• Signaling Pathways: Activates PLCγ1, PI3K, and Erk1/2 within minutes .

Hypothetical "GATA28 Antibody" Considerations

If "GATA28" refers to a bispecific antibody targeting GATA3 and CD28, no such construct has been reported. Potential design challenges include:

• Epitope Conflict: GATA3 is nuclear, while CD28 is membrane-bound.

• Functional Interference: Simultaneous targeting could disrupt T-cell differentiation and activation checkpoints.

Research Gaps and Opportunities

• Safety: CD28 superagonists require engineered variants (e.g., E1P2) to avoid CRS while preserving co-stimulation .

• Therapeutic Potential: Combining GATA3 inhibition with CD28 costimulation might modulate Th2-driven pathologies (e.g., allergies).